Advertisement
Screener

Vaxart, Inc. (VXRT) Pre-Tax Income

2.8 / 5 stars · 68/120 Roast Me

Vaxart, Inc. Pre-Tax Income

Vaxart, Inc. (VXRT) reported Pre-Tax Income of -$13.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06

  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$13.46M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $5.21M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $55.39M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$8.12M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$82.20M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$107.69M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2021 was -$70.36M.
  • Vaxart, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2020 was -$31.98M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed
2026-06-30-$13.46M
10-Q · filed 2026-08-06
-$8.26M
10-Q · filed 2026-08-06
$47.13M
derived: sum of 3 quarters · filed 2026-08-06
$39.01M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$5.21M
S-1 · filed 2026-05-08
$60.60M
derived: sum of 2 quarters · filed 2026-05-08
$52.47M
derived: sum of 3 quarters · filed 2026-05-08
$37.51M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$55.39M
derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08
$47.27M
derived: sum of 2 quarters · filed 2026-05-08
$32.30M
derived: sum of 3 quarters · filed 2026-08-06
$16.80M
S-1 · filed 2026-05-08
2025-09-30-$8.12M
10-Q · filed 2025-11-13
-$23.09M
derived: sum of 2 quarters · filed 2026-08-06
-$38.59M
10-Q · filed 2025-11-13
-$50.40M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$14.97M
10-Q · filed 2026-08-06
-$30.46M
10-Q · filed 2026-08-06
-$42.27M
derived: sum of 3 quarters · filed 2026-08-06
-$56.33M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$15.50M
S-1 · filed 2026-05-08
-$27.30M
derived: sum of 2 quarters · filed 2026-05-08
-$41.37M
derived: sum of 3 quarters · filed 2026-05-08
-$57.81M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31-$11.81M
derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08
-$25.87M
derived: sum of 2 quarters · filed 2026-05-08
-$42.32M
derived: sum of 3 quarters · filed 2026-05-08
-$66.69M
S-1 · filed 2026-05-08
2024-09-30-$14.06M
10-Q · filed 2025-11-13
-$30.51M
derived: sum of 2 quarters · filed 2025-11-13
-$54.88M
10-Q · filed 2025-11-13
-$72.08M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$16.45M
10-Q · filed 2025-08-13
-$40.82M
10-Q · filed 2025-08-13
-$58.02M
derived: sum of 3 quarters · filed 2025-08-13
-$75.38M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$24.37M
10-Q · filed 2025-05-13
-$41.57M
derived: sum of 2 quarters · filed 2025-05-13
-$58.93M
derived: sum of 3 quarters · filed 2025-05-13
-$81.47M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$17.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$34.56M
derived: sum of 2 quarters · filed 2025-03-20
-$57.09M
derived: sum of 3 quarters · filed 2025-03-20
-$82.20M
10-K · filed 2025-03-20
2023-09-30-$17.36M
10-Q · filed 2024-11-13
-$39.89M
derived: sum of 2 quarters · filed 2024-11-13
-$65.00M
10-Q · filed 2024-11-13
-$88.91M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$22.53M
10-Q · filed 2024-08-08
-$47.64M
10-Q · filed 2024-08-08
-$71.54M
derived: sum of 3 quarters · filed 2024-08-08
-$100.84M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$25.11M
10-Q · filed 2024-05-13
-$49.01M
derived: sum of 2 quarters · filed 2024-05-13
-$78.31M
derived: sum of 3 quarters · filed 2024-05-13
-$107.72M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$23.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$53.20M
derived: sum of 2 quarters · filed 2024-03-14
-$82.61M
derived: sum of 3 quarters · filed 2024-03-14
-$107.69M
10-K · filed 2024-03-14
2022-09-30-$29.29M
10-Q · filed 2023-11-02
-$58.71M
derived: sum of 2 quarters · filed 2023-11-02
-$83.79M
10-Q · filed 2023-11-02
-$104.53M
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30-$29.41M
10-Q · filed 2023-08-03
-$54.50M
10-Q · filed 2023-08-03
-$75.24M
derived: sum of 3 quarters · filed 2023-08-03
-$92.80M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$25.08M
10-Q · filed 2023-05-04
-$45.83M
derived: sum of 2 quarters · filed 2023-05-04
-$63.39M
derived: sum of 3 quarters · filed 2023-05-04
-$79.47M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31-$20.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
-$38.31M
derived: sum of 2 quarters · filed 2023-03-15
-$54.39M
derived: sum of 3 quarters · filed 2023-03-15
-$70.36M
10-K · filed 2023-03-15
2021-09-30-$17.56M
10-Q · filed 2022-11-09
-$33.65M
derived: sum of 2 quarters · filed 2022-11-09
-$49.62M
10-Q · filed 2022-11-09
-$63.45M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$16.09M
10-Q · filed 2022-08-08
-$32.05M
10-Q · filed 2022-08-08
-$45.88M
derived: sum of 3 quarters · filed 2022-08-08
-$53.94M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31-$15.97M
10-Q · filed 2022-05-09
-$29.80M
derived: sum of 2 quarters · filed 2022-05-09
-$37.86M
derived: sum of 3 quarters · filed 2022-05-09
2020-12-31-$13.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
-$21.89M
derived: sum of 2 quarters · filed 2022-02-24
-$31.98M
10-K · filed 2022-02-24
2020-09-30-$8.06M
10-Q · filed 2021-11-04
-$18.15M
10-Q · filed 2021-11-04
2019-12-31-$18.16M
10-K · filed 2022-02-24
2017-12-31-$3.30M
10-Q · filed 2018-02-06
-$8.60M
10-Q · filed 2018-02-06
-$14.50M
derived: sum of 3 quarters · filed 2018-02-06
-$18.70M
derived: sum of 4 quarters · filed 2018-02-06
2017-09-30-$5.30M
10-Q · filed 2017-11-07
-$11.20M
derived: sum of 2 quarters · filed 2017-11-07
-$15.40M
derived: sum of 3 quarters · filed 2017-11-07
-$24.40M
derived: sum of 4 quarters · filed 2018-02-06
2017-06-30-$5.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01
-$10.10M
derived: sum of 2 quarters · filed 2017-09-01
-$19.10M
derived: sum of 3 quarters · filed 2018-02-06
-$29.10M
10-K · filed 2017-09-01
2017-03-31-$4.20M
10-Q · filed 2017-05-08
-$13.20M
derived: sum of 2 quarters · filed 2018-02-06
-$23.20M
10-Q · filed 2017-05-08
-$30.20M
derived: sum of 4 quarters · filed 2018-02-06
2016-12-31-$9.00M
10-Q · filed 2018-02-06
-$19.00M
10-Q · filed 2018-02-06
-$26.00M
derived: sum of 3 quarters · filed 2018-02-06
-$31.20M
derived: sum of 4 quarters · filed 2018-02-06
2016-09-30-$10.00M
10-Q · filed 2017-11-07
-$17.00M
derived: sum of 2 quarters · filed 2017-11-07
-$22.20M
derived: sum of 3 quarters · filed 2017-11-07
-$28.70M
derived: sum of 4 quarters · filed 2017-11-07
2016-06-30-$7.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01
-$12.20M
derived: sum of 2 quarters · filed 2017-09-01
-$18.70M
derived: sum of 3 quarters · filed 2017-09-01
-$25.40M
10-K · filed 2017-09-01
2016-03-31-$5.20M
10-Q · filed 2017-05-08
-$11.70M
derived: sum of 2 quarters · filed 2017-05-08
-$18.40M
10-Q · filed 2017-05-08
-$38.30M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31-$6.50M
10-Q · filed 2017-02-06
-$13.20M
10-Q · filed 2017-02-06
-$33.10M
derived: sum of 3 quarters · filed 2017-02-06
-$31.90M
derived: sum of 4 quarters · filed 2017-02-06
2015-09-30-$6.60M
10-Q · filed 2015-11-06
-$26.60M
derived: sum of 2 quarters · filed 2016-09-13
-$25.40M
derived: sum of 3 quarters · filed 2016-09-13
-$18.90M
derived: sum of 4 quarters · filed 2016-09-13
2015-06-30-$20.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13
-$18.80M
derived: sum of 2 quarters · filed 2016-09-13
-$12.30M
derived: sum of 3 quarters · filed 2016-09-13
-$19.20M
10-K · filed 2016-09-13
2015-03-31$1.20M
10-Q · filed 2016-05-10
$7.70M
derived: sum of 2 quarters · filed 2016-05-10
$800.00K
10-Q · filed 2016-05-10
-$9.60M
derived: sum of 4 quarters · filed 2016-09-13
2014-12-31$6.50M
10-Q · filed 2016-02-08
-$400.00K
10-Q · filed 2016-02-08
-$10.80M
derived: sum of 3 quarters · filed 2016-09-13
-$7.60M
derived: sum of 4 quarters · filed 2016-09-13
2014-09-30-$6.90M
10-Q · filed 2015-11-06
-$17.30M
derived: sum of 2 quarters · filed 2016-09-13
-$14.10M
derived: sum of 3 quarters · filed 2016-09-13
-$14.20M
derived: sum of 4 quarters · filed 2016-09-13
2014-06-30-$10.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13
-$7.20M
derived: sum of 2 quarters · filed 2016-09-13
-$7.30M
derived: sum of 3 quarters · filed 2016-09-13
-$11.30M
10-K · filed 2016-09-13
2014-03-31$3.20M
10-Q · filed 2015-05-08
$3.10M
derived: sum of 2 quarters · filed 2015-05-08
-$900.00K
10-Q · filed 2015-05-08
-$7.20M
derived: sum of 4 quarters · filed 2015-09-11
2013-12-31-$100.00K
10-Q · filed 2015-02-06
-$4.10M
10-Q · filed 2015-02-06
-$10.40M
derived: sum of 3 quarters · filed 2015-09-11
-$10.20M
derived: sum of 4 quarters · filed 2015-09-11
2013-09-30-$4.00M
10-Q · filed 2014-11-07
-$10.30M
derived: sum of 2 quarters · filed 2015-09-11
-$10.10M
derived: sum of 3 quarters · filed 2015-09-11
-$5.50M
derived: sum of 4 quarters · filed 2015-09-11
2013-06-30-$6.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11
-$6.10M
derived: sum of 2 quarters · filed 2015-09-11
-$1.50M
derived: sum of 3 quarters · filed 2015-09-11
-$8.80M
10-K · filed 2015-09-11
-$8.60M
10-K · filed 2013-09-27
2013-03-31$200.00K
10-Q · filed 2014-05-12
$203.00K
10-Q · filed 2013-05-10
$4.80M
derived: sum of 2 quarters · filed 2014-05-12
-$2.50M
10-Q · filed 2014-05-12
-$2.31M
10-Q · filed 2013-05-10
-$8.41M
derived: sum of 4 quarters · filed 2014-09-30
2012-12-31$4.60M
10-Q · filed 2014-02-10
$4.82M
10-Q · filed 2013-02-11
-$2.70M
10-Q · filed 2014-02-10
-$2.52M
10-Q · filed 2013-02-11
-$8.61M
derived: sum of 3 quarters · filed 2014-09-30
-$10.50M
derived: sum of 4 quarters · filed 2014-09-30
2012-09-30-$7.30M
10-Q · filed 2013-11-12
-$13.21M
derived: sum of 2 quarters · filed 2014-09-30
-$15.10M
derived: sum of 3 quarters · filed 2014-09-30
-$22.67M
derived: sum of 4 quarters · filed 2014-09-30
2012-06-30-$5.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-30
-$7.80M
derived: sum of 2 quarters · filed 2014-09-30
-$15.37M
derived: sum of 3 quarters · filed 2014-09-30
-$19.70M
10-K · filed 2014-09-30
2012-03-31-$1.89M
10-Q · filed 2013-05-10
-$9.47M
derived: sum of 2 quarters · filed 2013-05-10
-$13.79M
10-Q · filed 2013-05-10
2011-12-31-$7.58M
10-Q · filed 2013-02-11
-$11.90M
10-Q · filed 2013-02-11
2011-06-30-$26.20M
10-K · filed 2013-09-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
EXOZYMES INC. (EXOZ)United States$0.058B